Vaccines List

M72/AS01E Tuberculosis Vaccine

M72/AS01E is a subunit vaccine candidate comprised of an immunogenic fusion protein (M72) derived from two Mycobacterium tuberculosis (M.tb) antigens (MTB32A and MTB39A), and the GlaxoSmithKline proprietary adjuvant AS01E.Read more...

mAb114 Ebola Therapeutic Vaccine

mAb114 is a human IgG1 MAb targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).  mAb114 is a single monoclonal antibody which binds to the core receptor binding domain of the Zaire ebolavirus surface protein, preventing the virus from infecting human cellsRead more...

Menactra Meningococcal Vaccine

Menactra contains N meningitidis serogroup 8 A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid 9 protein. N meningitidis A, C, Y, and W-135 strains are cultured on Mueller Hinton agar and 10 grown in Watson Scherp media containing casamino acid.Read more...

Menveo Meningococcal Vaccine

Menveo consists of two portions: 10 µg of lyophilized meningococcal serogroup A capsular polysaccharide conjugated to CRM197 and 5 μg each of capsular polysaccharide of serogroup C, W, and Y conjugated to CRM197 in 0.5 mL of phosphate-buffered saline, which is used to reconstitute the lyophilized MenA component.Read more...

MMR II Measles Vaccine

M-M-R II is also known as Measles, Mumps, and Rubella Virus Vaccine Live, is a live virus vaccine, containing weakened forms of measles virus, mumps virus, and rubella virus.Read more...

MMR II Mumps Vaccine

M-M-R II is also known as Measles, Mumps, and Rubella Virus Vaccine Live, is a live virus vaccine, containing weakened forms of measles virus, mumps virus, and rubella virus.Read more...

MMR II Rubella Vaccine

M-M-R II is also known as Measles, Mumps, and Rubella Virus Vaccine Live, is a live virus vaccine, containing weakened forms of measles virus, mumps virus, and rubella virus.Read more...

Mosquirix Malaria Vaccine

Mosquirix (RTS,S/AS01) is a recombinant vaccine consisting of the P. falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage.Read more...

mRNA-1647 Cytomegalovirus Vaccine

mRNA-1647 is a vaccine candidate combining six mRNAs in a single vial, which encode for two antigens on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB)Read more...

mRNA-1653 hMPV+PIV3 Vaccine

mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.Read more...

mRNA-1893 Zika Vaccine

mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection.Read more...

mRNA-1944 Chikungunya Vaccine

mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against Chikungunya infection.Read more...

mRNA-4157 Cancer Vaccine

mRNA-4157 is a therapeutic vaccine candidate that is a combination of validated defined neoantigens, predicted neoepitopes and mutations in driver genes into a single mRNA concatemer (mRNA-4650).Read more...

Multimeric-001 Influenza Vaccine

Multimeric-001 (M-001) is a recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.Read more...

MV-CHIK Chikungunya Vaccine

MV-CHIK is a vaccine candidate utilizing Themis’ measles vector platform. MV-CHIK consists of a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins.Read more...

MVA-M1+NP Influenza A Vaccine

MVA-M1+NP vaccine candidate consists of MVA, a replication-deficient pox viral vector that has been safely tested in thousands of patients, to generate a strong immune reaction against Matrix 1 (M1) and Nucleoprotein (NP) influenza antigens. Read more...